
VENUS #ACC20/#WCCardio

Trial Description: Patients with persistent AF were randomized in a 1:1.15 single-blind fashion to either catheter ablation + vein of Marshall (VOM) ablation vs. standard catheter ablation. Patients were followed for 12 months.



RESULTS

- Primary endpoint, freedom from AT/AF ≥30 seconds after 3 months, VOM ablation + catheter ablation vs. standard catheter ablation: 49.2% vs. 38% (p = 0.037)
- Freedom from AT/AF at 90 days: 62.2% vs. 53.8% (p = 0.09); zero AT/AF on 6- and 12month monitoring: 76.1% vs. 67.8% (p = 0.029)
- Total procedure time: 215.9 vs. 190.3 minutes (p = 0.001)

CONCLUSIONS

- This single-center, single-blind trial indicates that concomitant VOM alcohol ablation among patients with persistent AF undergoing catheter ablation is superior to standard catheter ablation alone
- These are important findings and will need to be validated in larger studies

Presented by Dr. Miguel Valderrábano at ACC.20/WCC



AMERICAN COLLEGE of